SCHEMBL35211140

SCHEMBL35211140

COc1cc2c3n(nc2c(Cl)c1Cl)CCN(C(=O)CCl)C3C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.36
▸ KDM4E B2RXH2 4/20 0.36
▸ LMNA P02545 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MITF O75030 1/20 0.36
▸ XBP1 P17861 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ KMT2A Q03164 6/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ CCR1 P32246 3/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ MTNR1A P48039 1/20 0.32
▸ MTNR1B P49286 1/20 0.32
▸ DRD2 P14416 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ YAP1 P46937 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35210835 1.00 ALDH1A1 (0.36) ALDH1A1KDM4ELMNANPC1MITF
SCHEMBL35212409 0.93 CCR1 (0.33) LMNAKMT2AMEN1CCR1CYP3A4
SCHEMBL35212060 0.93 CCR1 (0.33) LMNAKMT2AMEN1CCR1CYP3A4
SCHEMBL35212408 0.93 CCR1 (0.33) LMNAKMT2AMEN1CCR1CYP3A4
SCHEMBL35212553 0.93 CCR1 (0.33) LMNAKMT2AMEN1CCR1CYP3A4
SCHEMBL35211306 0.91 KMT2A (0.35) ALDH1A1KDM4ELMNANPC1MITF
SCHEMBL35211486 0.91 KMT2A (0.32) KMT2AMEN1CCR1CYP3A4CYP2C19
SCHEMBL35211047 0.91 KMT2A (0.32) KMT2AMEN1CCR1CYP3A4CYP2C19
SCHEMBL35211434 0.91 KMT2A (0.32) KMT2AMEN1CCR1CYP3A4CYP2C19
SCHEMBL35210838 0.87 CCNT1 (0.34) ALDH1A1KDM4EHTTKMT2ACCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF CGAS, GMPS, PRKG1 ALDH1A1 1171/4885KDM4E 4737/4885LMNA 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback